Accelerating research and treatment for Castleman Disease

Using The SomaScan® Assay to identify promising treatment approaches for Castleman Disease

Abstract

Background: Idiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias, and life-threatening multi-organ dysfunction. The molecular underpinnings of interleukin-6 (IL-6) blockade–refractory patients remain unknown; no targeted therapies exist. In this study, we searched for therapeutic targets in IL-6 blockade–refractory iMCD patients with the thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfunction, organomegaly (TAFRO) clinical subtype.

Methods: Serum and plasma were isolated for iMCD-1 following standard protocols, stored at –80°C, and shipped overnight on dry ice to Myriad RBM (serum) and SomaLogic, Inc. (plasma) for analysis. Proteomic quantifications were performed in accordance with previously published methods for Myriad RBM Discovery MAP v.3.3, a multiplex immunoassay that quantifies the levels of 315 analytes, and a previous version of SomaLogic SomaScan®, a modified DNA-aptamer approach that quantifies 1129 analytes (the current version of SomaScan® quantifies over 7,000 analytes).

Results: Studies of 3 IL-6 blockade–refractory iMCD cases revealed increased CD8+ T cell activation, VEGF-A, and PI3K/Akt/mTOR pathway activity. Administration of sirolimus substantially attenuated CD8+ T cell activation and decreased VEGF-A levels. Sirolimus induced clinical benefit responses in all 3 patients with durable and ongoing remissions of 66, 19, and 19 months.

Conclusion: This precision medicine approach identifies PI3K/Akt/mTOR signaling as the first pharmacologically targetable pathogenic process in IL-6 blockade–refractory iMCD. Prospective evaluation of sirolimus in treatment-refractory iMCD is planned (NCT03933904).

Headshot_D.Fajgenbaum-275x300

David Fajgenbaum, MD, MBA, MSc

Assistant Professor of Translational Medicine and Human Genetics, University of Pennsylvania

In addition to his rare disease research credentials at University of Pennsylvania, Dr. Fajgenbaum is also a patient battling idiopathic multicentric Castleman disease (iMCD). He became ill during his third year of medical school in 2010, had his last rites read, and had 4 life-threatening iMCD relapses. In 2012, Dr. Fajgenbaum cofounded the Castleman Disease Collaborative Network (CDCN). He currently leads 18 translational research studies, including an international natural history study, the first-ever NIH R01 grant studying iMCD, and a clinical trial of sirolimus in iMCD.

Leveraging serum proteomics to identify novel therapeutic approaches and predictive biomarkers

A webinar presented by David Fajgenbaum, MD, MBS, MSc


Share with colleagues

More webinars

WebinarMapping the human mucosal immune response to respiratory viruses

Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.

Learn more

WebinarAccelerating precision medicine of cancer with SomaScan® proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Learn more

WebinarImproving clinical development productivity with high-plex proteomics

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.

Learn more